Effects on cardiac function of a novel low viscosity plasma expander based on polyethylene glycol conjugated albumin

Minerva Anestesiologica

Volumn 77, Issue 7, 2011, Pages 704-714

  Chatpun, S ^a,b   Cabrales, P ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Cardiac; Catheter; Hemodilution; Hemorrhagic; Indwelling; Physiology; Resuscitation; Shock

Indexed keywords

DEXTRAN; DEXTRAN 2000; DEXTRAN 70; HUMAN SERUM ALBUMIN MACROGOL CONJUGATE; PLASMA SUBSTITUTE; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL OBSERVATION; COLLOID; CONTROLLED STUDY; EXPERIMENTAL MODEL; HEART CATHETER; HEART FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART OUTPUT; HEART STROKE VOLUME; HEART WORK; HEMODILUTION; HEMORRHAGIC SHOCK; HOMEOSTASIS; MALE; MOLECULAR WEIGHT; NONHUMAN; PLASMA TRANSFUSION; SHEAR RATE; SYRIAN HAMSTER; VISCOSITY;

ANIMALS; BLOOD PRESSURE; CRICETINAE; HEART; HEART FUNCTION TESTS; HEART RATE; HEMODILUTION; MALE; MESOCRICETUS; MOLECULAR WEIGHT; PLASMA SUBSTITUTES; POLYETHYLENE GLYCOLS; SERUM ALBUMIN; SHOCK, HEMORRHAGIC; VENTRICULAR FUNCTION, LEFT; VISCOSITY;

EID: 79959495165     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Boldt J, Suttner S. Plasma substitutes. Minerva Anestesiol 2005;71:741-58.
2. Gattinoni L, Carlesso E, Caironi P. [Albumin administration: volume replacement or pharmacological treatment?]. Minerva Anestesiol 2005;71:27-40.
3. Madjdpour C, Heindl V, Spahn DR. Risks, benefits, alternatives and indications of allogenic blood transfusions. Minerva Anestesiol 2006;72:283-8.
4. Choi YS, Shim JK, Hong SW, et al. Comparing the effects of 5% albumin and 6% hydroxyethyl starch 130/0.4 on coagulation and inflammatory response when used as priming solutions for cardiopulmonary bypass. Minerva Anestesiol 2010;76:584-91.
5. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002;54:459-76.
6. Yoh Kodera AM, Misao H, Hiroyuki N, Asako I, Tomoo U, Yuji I. Pegylation of proteins and bioactive substances for medical and technical applications. Progress in Polymer Science 1998;23:1233-71.
7. Sahu RK, Nacharaju P, Manjula BN, et al. Induced plasma expander-like properties as a function of PEG-chains on extension arm facilitated PEGylation of albumin: "mushroom to brush-like" conformational transition of the PEG-albumin conjugate. Artif Cells Blood Substit Immobil Biotechnol 2009;37:245-56.
8. Li D, Hu T, Manjula BN, et al. Extension arm facilitated pegylation of alphaalpha-hemoglobin with modifications targeted exclusively to amino groups: functional and structural advantages of free Cys-93(beta) in the PEG-Hb adduct. Bioconjug Chem 2009;20:2062-70.
9. Meng F, Manjula BN, Smith PK, et al. PEGylation of human serum albumin: reaction of PEG-phenyl-isothiocyanate with protein. Bioconjug Chem 2008;19:1352-60.
10. Manjula BN, Tsai A, Upadhya R, et al. Site-specific PEGylation of hemoglobin at Cys-93(beta): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconjug Chem 2003;14:464-72.
11. Li D, Manjula BN, Acharya AS. Extension arm facilitated PEGylation of hemoglobin: correlation of the properties with the extent of PEGylation. Protein J 2006;25:263-74.
12. Hu T, Prabhakaran M, Acharya SA, et al. Influence of the chemistry of conjugation of poly(ethylene glycol) to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate. Biochem J 2005;392:555-64.
13. Cabrales P, Nacharaju P, Manjula BN, et al. Early difference in tissue pH and microvascular hemodynamics in hemorrhagic shock resuscitation using polyethylene glycolalbumin-and hydroxyethyl starch-based plasma expanders. Shock 2005;24:66-73.
14. Cabrales P, Tsai AG, Winslow RM, et al. Extreme hemodilution with PEG-hemoglobin vs. PEG-albumin. Am J Physiol 2005;289:H2392-2400.
15. Martini J, Cabrales P, K A, et al. Survival time in severe hemorrhagic shock after perioperative hemodilution is longer with PEG-conjugated human serum albumin than with HES 130/0.4: a microvascular perspective. Crit Care 2008;12:R54.
16. Winslow RM, Lohman J, Malavalli A, et al. Comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat. J Appl Physiol 2004;97:1527-34.
17. Georgakopoulos D, Mitzner WA, Chen CH, et al. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol 1998;274:H1416-22.
18. Pacher P, Mabley JG, Liaudet L, et al. Left ventricular pressure-volume relationship in a rat model of advanced agingassociated heart failure. Am J Physiol Heart Circ Physiol 2004;287:H2132-7.
19. Westermann D, Mersmann J, Melchior A, et al. Biglycan is required for adaptive remodeling after myocardial infarction. Circulation 2008;117:1269-76.
20. Nishio R, Sasayama S, Matsumori A. Left ventricular pressure-volume relationship in a murine model of congestive heart failure due to acute viral myocarditis. J Am Coll Cardiol 2002;40:1506-14.
21. Pacher P, Nagayama T, Mukhopadhyay P, et al. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 2008;3:1422-34.
22. Baan J, van der Velde ET, de Bruin HG, et al. Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation 1984;70:812-23.
23. Chatpun S, Cabrales P. Cardiac Systolic Function Recovery After Hemorrhage Determines Survivability During Shock. J Trauma 2010 Aug 27. [Epub ahead of print].
24. Lee JS, Gladwin MT. Bad blood: the risks of red cell storage. Nat Med 2010;16:381-2.
25. Mirhashemi S, Ertefai S, Messmer K, et al. Model analysis of the enhancement of tissue oxygenation by hemodilution due to increased microvascular flow velocity. Microvasc Res 1987;34:290-301.
26. Kimura A, Okumura K, Mokuno S, et al. Higher viscosity participates in the regulation of coronary flow via nitric oxide and indomethacin-sensitive contracting factor. Can J Physiol Pharmacol 2004;82:1096-102.
27. Martini J, Carpentier B, Negrete AC, et al. Paradoxical hypotension following increased hematocrit and blood viscosity. Am J Physiol Heart Circ Physiol 2005;289:H2136-2143.
28. Martini J, Carpentier B, Chavez Negrete A, et al. Beneficial effects due to increasing blood and plasma viscosity. Clin Hemorheol Microcirc 2006;35:51-7.
29. Tsai AG, Acero C, Nance PR, et al. Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. Am J Physiol Heart Circ Physiol 2005;288:H1730-1739.
30. Yalcin O, Ulker P, Yavuzer U, et al. Nitric oxide generation by endothelial cells exposed to shear stress in glass tubes perfused with red blood cell suspensions: role of aggregation. Am J Physiol Heart Circ Physiol 2008;294:H2098-2105.
31. Cabrales P, Tsai AG, Intaglietta M. Microvascular pressure and functional capillary density in extreme hemodilution with low-and high-viscosity dextran and a low-viscosity Hb-based O2 carrier. Am J Physiol Heart Circ Physiol 2004;287:H363-373.
32. Cabrales P, Tsai AG, Winslow RM, et al. Extreme hemodilution with PEG-hemoglobin vs. PEG-albumin. Am J Physiol Heart Circ Physiol 2005;289:H2392-2400.
33. Evans TW. Review article: albumin as a drug--biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002;16 Suppl 5:6-11.
34. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005;41:1211-9.
35. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ 1998;317:235-40.
36. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-56.
37. Nohe B, Dieterich HJ, Eichner M, et al. Certain batches of albumin solutions influence the expression of endothelial cell adhesion molecules. Intensive Care Med 1999; 25:1381-5.